Delivery Order 36F79720D0180-36C24525N0558
Award Date
4/11/25
Potential Completion Date
4/18/25
Potential Value
$34K
Federal Agency
Veterans Integrated Service Network 5
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Cary, NC 27513, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of Kymriah, a specialized cell therapy cancer treatment, to the Department of Veterans Affairs (VA) through a Blanket Purchase Agreement (BPA) under Novartis Pharmaceuticals Corporation's Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs. The BPA, valued at $283,555.92, was issued by the VA's Veterans Integrated Service Network 9 and has a completion date of January 29, 2021. Novartis Pharmaceuticals Corporation, a foreign-owned,...
The Department of Veterans Affairs Veterans Health Administration awarded a $283,567.92 delivery order to Novartis Pharmaceuticals Corporation (doing business as NPS), a foreign-owned for-profit manufacturer of pharmaceuticals and drugs. The order was placed against Novartis' Federal Supply Schedule 61-IB contract for pharmaceuticals and drugs, which has a total potential value of $5.4 billion and runs through August 2025. The delivery order was for Novartis' Kymriah, a chimeric antigen receptor...
The Department of Veterans Affairs (VA) awarded a $283,526.57 firm fixed price delivery order to Novartis Pharmaceuticals Corporation, a foreign-owned for-profit manufacturer, to provide the emergency cancer treatment Tisagenlecleucel under the VA's Federal Supply Schedule contract for pharmaceuticals and drugs. The delivery order was issued by the VA Veterans Health Administration's Veterans Integrated Service Network 9 and did not have a set-aside designation. Novartis holds a $5.4 billion...
This federal contract award to Novartis Pharmaceuticals Corporation, doing business as NPS, is for the delivery of Kymriah, a specialized cell therapy cancer treatment, to the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The contract is issued as a delivery order against Novartis' existing Federal Supply Schedule (FSS) 61-IB contract for pharmaceuticals and drugs, which has a potential value of $5.4 billion and runs through August 2025. The specific delivery...
This federal contract award is for the pharmaceutical product Kymriah (tisagenlecleucel), a chimeric antigen receptor T-cell (CAR-T) therapy, provided by the prime contractor Novartis Pharmaceuticals Corporation. The contract has a ceiling value of $283,555.92 and is a Blanket Purchase Agreement (BPA) call under Novartis' Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract was awarded by the Department of Veterans Affairs (VA) and is intended to support...
This is a federal contract award from the U.S. Department of Veterans Affairs (VA) to Novartis Vaccines And Diagnostics, Inc. for the delivery of drugs and biologicals. The contract has a ceiling value of $262,467.00 and is a Firm Fixed Price Delivery Order. The contract does not have a set-aside designation. The award was made on May 16, 2007, with an ultimate completion date of September 11, 2007. The place of performance is Phoenix, Arizona. Novartis Vaccines And Diagnostics, Inc. is a...
This contract award by the Veterans Integrated Service Network 22 (VISN 22) of the U.S. Department of Veterans Affairs is for the delivery of pharmaceutical flu vaccines, a biological product. The contract was awarded to Novartis Vaccines and Diagnostics, Inc., a for-profit foreign-owned manufacturer, on June 4, 2015 and has a firm fixed price ceiling value of $143,000.00. The contract is not associated with a set-aside program and has an ultimate completion date of March 31, 2016. This award...
This federal contract award is a firm fixed-price delivery order issued by the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The contract, valued at $485,835.00, is for the supply of DALFAMPRIDINE 100 MG, a medication used to treat Parkinson's disease and multiple sclerosis symptoms. The contract was awarded on January 17, 2017, with a final completion date of...
<p>This is a firm fixed-price delivery order awarded by the Veterans Integrated Service Network 19 (VISN 19), a civilian agency of the U.S. Department of Veterans Affairs, to Novartis Vaccines and Diagnostics, Inc., a foreign-owned for-profit manufacturer. The contract, valued at $135,200.00, is for pharmacy orders and does not have a set-aside designation. No further details about larger contract vehicles or subcontractors are provided.</p>
This federal contract award was made by the Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company specializing in neurological disorders. The contract is for the delivery of DALFAMPRIDINE, which is likely a medication used to treat Parkinson's disease and multiple sclerosis. The contract was awarded as a Firm Fixed Price Delivery Order under Acorda's Federal Supply Schedule (FSS) contract with the VA, valued at over $16.3 million. The contract has a ceiling...